Terms: = Lymphoma AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Clinical Outcome
13 results:
1. Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients.
Li D; Jiang H; Jin F; Pan L; Xie Y; Zhang L; Li C
Genes Genomics; 2023 Jan; 45(1):93-102. PubMed ID: 36445572
[TBL] [Abstract] [Full Text] [Related]
2. Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement.
Bomken S; Enshaei A; Schwalbe EC; Mikulasova A; Dai Y; Zaka M; Fung KTM; Bashton M; Lim H; Jones L; Karataraki N; Winterman E; Ashby C; Attarbaschi A; Bertrand Y; Bradtke J; Buldini B; Burke GAA; Cazzaniga G; Gohring G; De Groot-Kruseman HA; Haferlach C; Nigro LL; Parihar M; Plesa A; Seaford E; Sonneveld E; Strehl S; Van der Velden VHJ; Rand V; Hunger SP; Harrison CJ; Bacon CM; Van Delft FW; Loh ML; Moppett J; Vormoor J; Walker BA; Moorman AV; Russell LJ
Haematologica; 2023 Mar; 108(3):717-731. PubMed ID: 35484682
[TBL] [Abstract] [Full Text] [Related]
3. Distribution of molecular subtypes of advanced lung adenocarcinoma and clinical outcomes in a center of Argentina.
Recondo G; Denninghoff V; Cuello MT; Lorente C; Greco M; De la Vega M; Avagnina A; Recondo G
Medicina (B Aires); 2018; 78(6):385-394. PubMed ID: 30504104
[TBL] [Abstract] [Full Text] [Related]
4. Next-generation sequencing-based characterization of the invasion by anatomical contiguity in a primary osseous diffuse large B-cell lymphoma. Correlation between the genetic profile of the malignancy and the clinical outcome of the patient.
Zaharie F; Pop LA; Petrushev B; Jurj A; Muresan MS; Eniu D; Fetica B; Petkov B; Pasca S; Piciu D; Rus I; Deak D; Dima D; Desmirean MS; Tomuleasa C; Berindan-Neagoe I
Histol Histopathol; 2019 Jun; 34(6):663-670. PubMed ID: 30467824
[TBL] [Abstract] [Full Text] [Related]
5. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group.
Roberts KG; Reshmi SC; Harvey RC; Chen IM; Patel K; Stonerock E; Jenkins H; Dai Y; Valentine M; Gu Z; Zhao Y; Zhang J; Payne-Turner D; Devidas M; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Mattano LA; Maloney KW; Carroll WL; Loh ML; Willman CL; Gastier-Foster JM; Mullighan CG; Hunger SP
Blood; 2018 Aug; 132(8):815-824. PubMed ID: 29997224
[TBL] [Abstract] [Full Text] [Related]
6. clinical outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or kras Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract] [Full Text] [Related]
7. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
[TBL] [Abstract] [Full Text] [Related]
8. Clonal and microclonal mutational heterogeneity in high hyperdiploid acute lymphoblastic leukemia.
de Smith AJ; Ojha J; Francis SS; Sanders E; Endicott AA; Hansen HM; Smirnov I; Termuhlen AM; Walsh KM; Metayer C; Wiemels JL
Oncotarget; 2016 Nov; 7(45):72733-72745. PubMed ID: 27683039
[TBL] [Abstract] [Full Text] [Related]
9. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
[TBL] [Abstract] [Full Text] [Related]
10. Novel drugs against non-small-cell lung cancer.
Pirker R
Curr Opin Oncol; 2014 Mar; 26(2):145-51. PubMed ID: 24406751
[TBL] [Abstract] [Full Text] [Related]
11. clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to kras mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract] [Full Text] [Related]
12. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and kras mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract] [Full Text] [Related]
13. N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis.
Lübbert M; Mirro J; Miller CW; Kahan J; Isaac G; Kitchingman G; Mertelsmann R; Herrmann F; McCormick F; Koeffler HP
Blood; 1990 Mar; 75(5):1163-9. PubMed ID: 2407301
[TBL] [Abstract] [Full Text] [Related]
